Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.1111/dom.13028
Abstract: The aim was to determine the effects of dulaglutide, a synthetic once‐weekly, injectable human glucagon‐like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2… read more here.
Keywords: effects dulaglutide; trial; researching cardiovascular; baseline ... See more keywords